Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Biopharmaceutical approaches have been used to target key elements in the processes controlling airway inflammation in asthma and COPD. There is compelling evidence that IL-13 is a key mediator in the inflammatory processes in the asthmatic lung. Tralokinumab (CAT-354), under development by MedImmune, is an injectable, anti-IL-13 humanized mAb for the potential treatment of asthma and COPD. In a study in mice, tralokinumab prevented the development of the asthmatic phenotype, including eosinophil recruitment and airway hyperresponsiveness. In clinical trials, tralokinumab demonstrated favorable safety and pharmacokinetic profiles, both in healthy volunteers and in patients with asthma. This review summarizes the problems and successes regarding recent developments in mAb-based strategies targeted against IL-13 in asthma and COPD, with an emphasis on tralokinumab.

Original languageEnglish
Pages (from-to)1305-1312
Number of pages8
JournalCurrent Opinion in Investigational Drugs
Volume11
Issue number11
Publication statusPublished - Nov 2010

Keywords

  • airway smooth-muscle
  • anti-human-interleukin-13 antibody CAT-354
  • obstructive pulmonary-disease
  • IL-13 neutralization
  • epithelial-cells
  • mast-cells
  • interleukin-13
  • inflammation
  • expression
  • cytokine

Cite this

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD. / Walsh, Garry Michael.

In: Current Opinion in Investigational Drugs, Vol. 11, No. 11, 11.2010, p. 1305-1312.

Research output: Contribution to journalArticle

@article{e13c5b2423614627aba091fbf8e06770,
title = "Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD",
abstract = "Biopharmaceutical approaches have been used to target key elements in the processes controlling airway inflammation in asthma and COPD. There is compelling evidence that IL-13 is a key mediator in the inflammatory processes in the asthmatic lung. Tralokinumab (CAT-354), under development by MedImmune, is an injectable, anti-IL-13 humanized mAb for the potential treatment of asthma and COPD. In a study in mice, tralokinumab prevented the development of the asthmatic phenotype, including eosinophil recruitment and airway hyperresponsiveness. In clinical trials, tralokinumab demonstrated favorable safety and pharmacokinetic profiles, both in healthy volunteers and in patients with asthma. This review summarizes the problems and successes regarding recent developments in mAb-based strategies targeted against IL-13 in asthma and COPD, with an emphasis on tralokinumab.",
keywords = "airway smooth-muscle, anti-human-interleukin-13 antibody CAT-354, obstructive pulmonary-disease, IL-13 neutralization, epithelial-cells, mast-cells, interleukin-13, inflammation, expression, cytokine",
author = "Walsh, {Garry Michael}",
year = "2010",
month = "11",
language = "English",
volume = "11",
pages = "1305--1312",
journal = "Current Opinion in Investigational Drugs",
issn = "1472-4472",
publisher = "Current Drugs Ltd.",
number = "11",

}

TY - JOUR

T1 - Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD

AU - Walsh, Garry Michael

PY - 2010/11

Y1 - 2010/11

N2 - Biopharmaceutical approaches have been used to target key elements in the processes controlling airway inflammation in asthma and COPD. There is compelling evidence that IL-13 is a key mediator in the inflammatory processes in the asthmatic lung. Tralokinumab (CAT-354), under development by MedImmune, is an injectable, anti-IL-13 humanized mAb for the potential treatment of asthma and COPD. In a study in mice, tralokinumab prevented the development of the asthmatic phenotype, including eosinophil recruitment and airway hyperresponsiveness. In clinical trials, tralokinumab demonstrated favorable safety and pharmacokinetic profiles, both in healthy volunteers and in patients with asthma. This review summarizes the problems and successes regarding recent developments in mAb-based strategies targeted against IL-13 in asthma and COPD, with an emphasis on tralokinumab.

AB - Biopharmaceutical approaches have been used to target key elements in the processes controlling airway inflammation in asthma and COPD. There is compelling evidence that IL-13 is a key mediator in the inflammatory processes in the asthmatic lung. Tralokinumab (CAT-354), under development by MedImmune, is an injectable, anti-IL-13 humanized mAb for the potential treatment of asthma and COPD. In a study in mice, tralokinumab prevented the development of the asthmatic phenotype, including eosinophil recruitment and airway hyperresponsiveness. In clinical trials, tralokinumab demonstrated favorable safety and pharmacokinetic profiles, both in healthy volunteers and in patients with asthma. This review summarizes the problems and successes regarding recent developments in mAb-based strategies targeted against IL-13 in asthma and COPD, with an emphasis on tralokinumab.

KW - airway smooth-muscle

KW - anti-human-interleukin-13 antibody CAT-354

KW - obstructive pulmonary-disease

KW - IL-13 neutralization

KW - epithelial-cells

KW - mast-cells

KW - interleukin-13

KW - inflammation

KW - expression

KW - cytokine

M3 - Article

VL - 11

SP - 1305

EP - 1312

JO - Current Opinion in Investigational Drugs

JF - Current Opinion in Investigational Drugs

SN - 1472-4472

IS - 11

ER -